Matching articles for "Brukinsa"
Issue 1759 · July 20, 2026
Sonrotoclax (Beqalzi) for Mantle Cell Lymphoma

The FDA has granted accelerated approval to the B-cell lymphoma 2 (BCL-2) inhibitor sonrotoclax ( Beqalzi – BeOne Medicines) for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who…

Med Lett Drugs Ther. 2026 Jul 20; 68(1759):e119-20 doi:10.58347/tml.2026.1759f
The FDA has granted accelerated approval to the B-cell lymphoma 2 (BCL-2) inhibitor sonrotoclax ( Beqalzi – BeOne Medicines) for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who received ≥2 prior lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor (e.g., pirtobrutinib [Jaypirca] ), acalabrutinib [Calquence] , or zanubrutinib [Brukinsa] ). Sonrotoclax is the first BCL-2 inhibitor to be approved in the US for this indication. The BCL-2 inhibitor venetoclax (Venclexta) has been used off label for third-line treatment of MCL.
Issue 1670 · February 20, 2023 Free
In Brief: Zanubrutinib (Brukinsa) for CLL or SLL (online only)

The Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) , which was previously approved by the FDA for treatment of mantle cell lymphoma, Waldenström's macroglobulinemia, and relapsed or…

Med Lett Drugs Ther. 2023 Feb 20; 65(1670):e33-4 doi:10.58347/tml.2023.1670e
The Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) , which was previously approved by the FDA for treatment of mantle cell lymphoma, Waldenström's macroglobulinemia, and relapsed or refractory marginal zone lymphoma, has now been approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults. The BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) were approved earlier for treatment of CLL and SLL.
Issue 1670 · February 20, 2023
Pirtobrutinib (Jaypirca): A Fourth Bruton's Tyrosine Kinase Inhibitor for Mantle Cell Lymphoma (online only)

The Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib ( Jaypirca – Lilly) has received accelerated approval from the FDA for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who…

Med Lett Drugs Ther. 2023 Feb 20; 65(1670):e35-6 doi:10.58347/tml.2023.1670f
The Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib ( Jaypirca – Lilly) has received accelerated approval from the FDA for treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults who received ≥2 prior lines of systemic therapy, including a BTK inhibitor. Accelerated approval was based on the response rate. The BTK inhibitors ibrutinib (Imbruvica) , acalabrutinib (Calquence) , and zanubrutinib (Brukinsa) are also approved for treatment of MCL.